Why gross to net is a data problem as much as a finance one
Gross to net is the distance between what a brand books at list price and what it actually keeps. Gross sales are units multiplied by the wholesale acquisition cost. Net sales are what remains after every chargeback, rebate, discount, fee, copay program and return has been taken off. For many specialty brands that distance is now one of the largest lines in the P&L, and one of the least visible to the commercial and access teams whose decisions drive it.
The difficulty is that most deductions are not known when the unit ships. A Medicaid rebate is invoiced by a state after the quarter closes. A commercial rebate depends on utilization the PBM reports later. A copay program cost depends on which patients used the card and how much their plan design pushed onto it. So finance books accruals, its best estimate of each deduction, and trues them up months later when the invoices arrive.
Those estimates are only as good as the data under them. Which channel did each unit go through? Which payer covered the patient on the day of the fill? Was the dispense eligible for a 340B price? When those questions are answered with averages instead of unit level facts, the net price forecast moves at every true-up and nobody can explain why. This article sets out the parts of the waterfall, where the data usually breaks, and how to build a gross to net view that commercial, access and finance can all read. It builds on our guides to specialty pharmacy data and the pharma commercial data warehouse.
The parts of a specialty gross to net waterfall
Chargebacks
When a wholesaler sells to a customer with a contract price below list, such as a GPO member, a federal buyer or a 340B covered entity, the wholesaler claims back the difference from the manufacturer.
- Paid on wholesaler submissions
- Depend on the end customer, not the payer
- 340B units need identifying at the dispense
Government rebates
Medicaid rebates invoiced by states, Medicare Part D manufacturer discounts, and inflation rebates under the IRA. Each has its own rules, timing and data source.
- Invoiced after the quarter closes
- Driven by payer at the fill
- Duplicate discount checks with 340B
Commercial rebates and fees
Rebates negotiated with PBMs and health plans for formulary position, plus administrative fees. They are paid on reported utilization, often with tiers and conditions.
- Plan and PBM names must map to contracts
- Carve-outs change who reports the unit
- Lag of one or more quarters
Copay, channel fees and returns
Copay assistance paid on behalf of commercially insured patients, specialty pharmacy and hub service and data fees, prompt pay discounts and product returns.
- Copay cost moves with plan design
- Accumulators and maximizers change spend
- Fees tied to contracts, not units
Where gross to net data usually breaks
Payer is assigned at the wrong moment. The patient was commercial at referral, Medicaid by the third fill, and the accrual model uses the payer mix from the launch plan. Each of those is a different deduction. Gross to net needs the payer that covered each fill, which is a patient level fact, not a brand average.
Plan names never match contracts. Claims and specialty pharmacy feeds carry plan names, BIN, PCN and group numbers. Contracts are written by PBM and plan. Without a maintained payer hierarchy that links one to the other, utilization cannot be matched to the rebate that applies.
Copay spend is reported separately from the patient. The copay vendor sends program totals. The specialty pharmacy sends dispenses. If the two are not linked to the same patient, nobody can see which plan designs are driving copay cost, or whether an accumulator has started to drain the program.
Accruals and actuals live in different places. Finance holds the accrual model, access holds the contracts, and commercial holds the demand data. When the true-up arrives, the variance is explained in a meeting rather than in the data.
How to build a gross to net view leaders can read
Start from the waterfall finance already uses
List every deduction line, its data source, its timing and who owns it. This is the backbone of the view, not a new model.
Link units to patients and payers
Bring specialty pharmacy dispenses, hub cases and copay claims onto one linked patient, with the payer that covered each fill on its date.
Maintain the payer hierarchy
Map plan, BIN, PCN and group to PBM, plan and contract, with effective dates, so utilization meets the right rebate terms.
Show accrual against actual by line
For each deduction, show the estimate, the invoice when it arrives, and the variance, broken out by channel and payer rather than as one total.
Give commercial and access the same view
When a brand team can see how payer shifts and copay use move net price, gross to net stops being a surprise at quarter close.
Questions leaders ask about gross to net
What does gross to net mean in pharma?
Why do gross to net accruals change after the quarter closes?
Which data matters most for a specialty brand's gross to net?
How does payer mix affect gross to net?
Should commercial and access teams see gross to net?
Compare notes on your gross to net data
Tell us where your gross to net variance gets explained today, and which feeds sit under the accrual model. We will show where unit level data would narrow the gap. More on our work at specialty pharma analytics and automation.
Part of our Pharma Commercial and Patient Analytics hub. Start with our specialty pharmacy analytics.